Börse:

Sagimet Biosciences Inc.

[WKN: A3CPAM | ISIN: US7867001049]

6,550€ 1,55%

Echtzeit-Aktienkurs Sagimet Biosciences Inc.

Bid: Ask:

Nachrichten zur Sagimet Biosciences Inc. Aktie

» Nachrichtenticker öffnen

Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination

SAN MATEO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical…

What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?

Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investors? Lets find…

Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Heres What You Should Know

The mean of analysts price targets for Sagimet Biosciences Inc. (SGMT) points to a 437.1% upside in the stock. While…

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN MATEO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company…

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical…

‹
1
›